

**Date:** October 20, 2011  
**For Immediate Release**



**Contact:** Ashwin Pushpala  
(408) 483-6518

### **SinuSys welcomes new board member**

**Palo Alto, CA** – SinuSys Corporation, a medical device company focused on sinus health, recently named Dr. Peter Milner as the newest member of their board of directors. Milner is a partner at AshHill Pharmaceutical Investments, LLC. AshHill is a recent investor in the Series B financing of SinuSys Corporation.

Milner has co-founded several successful pharmaceutical and biomedical startups including Optivia Biotechnology, a private company now recognized as a leader in the emerging field of transporter biology, ARYx Therapeutics (NASDAQ: ARYX) and CV Therapeutics (NASDAQ: CVTX), which was later acquired by Gilead for \$1.5B in 2009. In 2005, he was instrumental in restructuring his family pharmaceutical company ML Laboratories (MLB:LSE) and its subsequent merger to form Vectura (VEC:LSE), a profitable company and one of the world's leading makers of inhaled products.

A board certified physician and cardiologist, Milner currently serves as voluntary clinical faculty at Stanford Veterans' Hospital. He is an inventor on 50 patents and has authored numerous scientific articles published in peer-reviewed journals.

Milner is a partner in AshHill Pharmaceutical Investments, LLC, which is a private limited liability company focused on creating maximum value for its members by investing in companies that develop products and services to serve the biopharmaceutical industry.

"Peter has tremendous experience and successes working with organizations like ours, so we are thrilled to have him join our board of directors," said Thomas Schreck, CEO of SinuSys. "His insight and innovative thinking will undoubtedly help us reach our overall objective of delivering treatments to those suffering from chronic sinusitis."

Schreck, along with Dr. Jerome Hester, co-founded Sinusys in 2010 in order to develop much needed therapies to help individuals afflicted with chronic sinusitis, a condition that affects more than 31 million people in the United States.

"I am honored to be a part of a team that consists of forward thinking individuals who are all working toward improving the lives of so many people," Milner said. "I'm looking forward to working with such an impressive group, developing truly remarkable, life-changing products."

For more information regarding SinuSys Corporation, or to learn more about Dr. Peter Milner, visit their website [www.sinusys.com](http://www.sinusys.com).

### **About SinuSys Corporation**

SinuSys Corporation ([www.sinusys.com](http://www.sinusys.com)) is a medical device company focused on developing new therapies to improve the sinus health of patients with chronic sinusitis.

**Date:** October 20, 2011  
**For Immediate Release**



**Contact:** Ashwin Pushpala  
(408) 483-6518

The company's initial focus is a self-expanding medical device inserted at the ostium of the maxillary sinus, which restores functional sinus drainage and ventilation without causing patient discomfort.

**About AshHill Pharmaceutical Investments, LLC**

AshHill provides equity capital to both seed-stage and established companies who have innovative pharmaceutical and medical device platforms that target significant healthcare needs. They are a private limited liability company focused on creating maximum value for its members by investing in companies that primarily develop innovative products and services in various stages of research, development and approval to serve the biopharmaceutical industry. [www.ashhill.net](http://www.ashhill.net)